Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab | Business Wire

Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab | Business Wire: Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products,